FDA approves pretomanid tablets in combination with bedaquiline and linezolid for treatment of extensively drug resistant, treatment-intolerant or nonresponsive multidrug resistant pulmonary TB

Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. A successful outcome has been reported in 95 of the first 107 patients in trial after six months of treatment with this regimen and six months of post-treatment follow-up.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news